Submit Deal

Daniel O'Day

Chairman and CEO at GILEAD SCIENCES

Manager

Deal Bio

Total Deals15

Valued Deals13

Total Value£28,538M

Avg. Deal Size£2,195M

Market Context

Expertise (15)

Key Relationships

Sort

United States

Medical Equipment

PrivateAcquisition

target

Flatiron Health

bidder

Roche Holdings

£1,522m

4 dealmakers

Belgium

Biotechnology

PublicAcquisitionMinorityCross Border

target

Galapagos

bidder

Gilead Sciences

£849m

36 dealmakers

United States

Biotechnology

AcquisitionPublicMajorityTender Offer

target

Forty Seven

bidder

Gilead Sciences

£3,821m

48 dealmakers

United States

Biotechnology

PublicMinorityAcquisition

target

Arcus Biosciences

bidder

Gilead Sciences

£162m

8 dealmakers

United States

Health Care Services

AcquisitionPrivateMinorityDomestic

target

Pionyr Immunotherapeutics

bidder

Gilead Sciences

£221m

24 dealmakers

United States

Medical Services

AcquisitionMinorityPrivateDomestic

target

Tizona Therapeutics

bidder

Gilead Sciences

£235m

43 dealmakers

United States

Pharmaceuticals

MajorityDomesticPublicAcquisitionTender Offer

target

IMMUNOMEDICS

bidder

Gilead Sciences

£16,407m

50 dealmakers

Germany

Biotechnology

AcquisitionCross BorderPrivateMajorityVenture CapitalPrivate Equity

target

Myr

bidder

Gilead Sciences

£1,309m

26 dealmakers

United Kingdom

Biotechnology

Cross BorderAcquisitionVenture CapitalPrivatePrivate EquityMinority

target

VACCITECH

bidder

Gilead Sciences

£121m

22 dealmakers

United States

Biotechnology

Private EquityDe-SPACReverse TakeoverPrivateDomesticMergerAcquisitionMajority

target

Tango Therapeutics

bidder

Cormorant Asset Management

£257m

32 dealmakers

United States

Biotechnology

MajorityMergerDe-SPACPrivate EquityDomesticAcquisitionPrivateReverse Takeover

target

Pardes Biosciences

bidder

Ecor1 Capital

£199m

37 dealmakers

United States

Biotechnology

Cross BorderMajorityInfrastructureAcquisitionPrivate

target

Gilead Sciences (kite Production Facility And Assets)

bidder

BIONTECH

value n/a

7 dealmakers

United States

Pharmaceuticals

DomesticPublicAcquisitionMinority

target

Hookipa Pharma

bidder

Gilead Sciences

£25m

11 dealmakers

United States

Biotechnology

PrivateAcquisitionMajorityDomestic

target

Tmunity Therapeutics

bidder

Kite Pharma

value n/a

29 dealmakers

United States

Pharmaceuticals

AcquisitionDomesticMajorityPublic

target

Cymabay Therapeutics

bidder

Gilead Sciences

£3,404m

30 dealmakers

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.